Overview
Hyperostosis corticalis generalisata, also known as Van Buchem disease, is a rare inherited skeletal disorder characterized by progressive thickening (hyperostosis) of the cortical bone throughout the body. The condition primarily affects the skull, mandible (jawbone), clavicles, ribs, and long bones. The excessive bone growth leads to a characteristic set of clinical features including enlargement and widening of the jaw, facial distortion, and cranial nerve compression. Compression of cranial nerves within narrowed bony foramina can result in facial nerve palsy (Bell's palsy), hearing loss, and visual impairment. Increased intracranial pressure may also occur due to thickening of the skull vault. The condition typically becomes apparent during childhood or puberty and progresses throughout life. The disease is caused by a deletion in the regulatory region downstream of the SOST gene on chromosome 17q21, which leads to reduced production of sclerostin, a protein that normally inhibits bone formation. Without adequate sclerostin, osteoblastic activity is excessive, resulting in continuous bone deposition. Van Buchem disease is inherited in an autosomal recessive manner and is particularly prevalent in a Dutch population from a village in the province of Groningen in the Netherlands, where a founder effect has been identified. There is currently no cure for hyperostosis corticalis generalisata. Treatment is primarily symptomatic and supportive. Surgical decompression of cranial nerves may be necessary to address facial palsy, hearing loss, or optic nerve compression. Regular monitoring by a multidisciplinary team including orthopedic specialists, neurologists, ophthalmologists, and audiologists is recommended. Interestingly, research into the SOST gene and sclerostin pathway has contributed significantly to the development of anti-sclerostin antibody therapies (such as romosozumab) for osteoporosis, though these therapies are not used to treat Van Buchem disease itself.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Hyperostosis corticalis generalisata.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Hyperostosis corticalis generalisata at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Hyperostosis corticalis generalisata.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Hyperostosis corticalis generalisata.
Community
No community posts yet. Be the first to share your experience with Hyperostosis corticalis generalisata.
Start the conversation →Latest news about Hyperostosis corticalis generalisata
No recent news articles for Hyperostosis corticalis generalisata.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Hyperostosis corticalis generalisata
What is Hyperostosis corticalis generalisata?
Hyperostosis corticalis generalisata, also known as Van Buchem disease, is a rare inherited skeletal disorder characterized by progressive thickening (hyperostosis) of the cortical bone throughout the body. The condition primarily affects the skull, mandible (jawbone), clavicles, ribs, and long bones. The excessive bone growth leads to a characteristic set of clinical features including enlargement and widening of the jaw, facial distortion, and cranial nerve compression. Compression of cranial nerves within narrowed bony foramina can result in facial nerve palsy (Bell's palsy), hearing loss,
How is Hyperostosis corticalis generalisata inherited?
Hyperostosis corticalis generalisata follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Hyperostosis corticalis generalisata typically begin?
Typical onset of Hyperostosis corticalis generalisata is childhood. Age of onset can vary across affected individuals.